Leerink Partners analyst Paul Matteis reiterated an Outperform rating and boosted his price target on Sage Therapeutics (NASDAQ: SAGE) to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change FDA

Goldman Sachs Starts Sage Therapeutics (SAGE) at BuyMay 15, 2015 7:02 AM Roth Capital Affirms Ligand Pharma (LGND) Following Positive SAGE-547 Update (SAGE)May 14, 2015 10:19 AM SAGE Therapeutics (SAGE) Misses Q1 EPS by 17cMay 14, 2015 6:33 AM SAGE Therapeutics Announces SAGE-547 Progress and First Quarter 2015 Financial ResultsMay 14, 2015 6:30 AM SAGE Therapeutics Announces SAGE-547 Progress and First Quarter 2015 Financial ResultsMay 14, 2015 6:30 AM SAGE Therapeutics (SAGE) Issues Positive Update on SAGE-547; Primary Endpoint MetMay 14, 2015 6:18 AM SAGE Therapeutics Achieves 77 Percent Response Rate in Completed Phase 1/2 Clinical Trial of SAGE-547 in Super-Refractory Status EpilepticusMay 14, 2015 6:15 AM